SABR-Dual: A phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low-and favorable intermediate-risk prostate cancer

Dose-escalated radiotherapy is known to improve progression free survival in patients with localized prostate cancer, and recent advances have led to the standardization of ultrahypofractionated stereotactic ablative radiotherapy (SABR) delivered in just 5-fractions. This study aims to evaluate the safety, efficacy, and non-inferiority of generalizable 2-fraction SABR compared to the current 5-fraction regimen.